{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-017116","form_type":"8-K","ticker":"AURX","cik":"0001091596","company_name":"Nuo Therapeutics, Inc.","filed_at":"2026-05-14T21:11:29+00:00","discovered_at":"2026-05-14T21:12:00.291393+00:00","generated_at":"2026-05-14T21:12:35.177578+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Nuo Therapeutics Q1 revenues up 169% YoY to $1.3M; operating loss narrows","bullets":["Total revenue $1.3M, including $1.22M product sales, up 169% YoY and 20% sequential.","Aurix branded product revenue rose over 30% sequentially versus Q4 2025.","Net operating loss improved to $446,000 from $745,000 in Q1 2025.","Entered $1.0M Loan and Security Agreement to fund growth as company approaches breakeven.","CEO cites strong Aurix demand and favorable Medicare reimbursement shift for autologous PRP."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-017116","json":"https://secwatch.observer/filing/0001437749-26-017116.json","markdown":"https://secwatch.observer/filing/0001437749-26-017116.md","text":"https://secwatch.observer/filing/0001437749-26-017116.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1091596/000143774926017116/0001437749-26-017116-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1091596/000143774926017116/aurx20260514_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T21:12:35.177578+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8b60c1fd32e9139fcd2e425ab192647dc78786e7","claim":"Nuo Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: revenue approximately $1.3 million.","evidence_excerpt":"results for the first quarter ended March 31, 2026 and provided an operational and business update. First Quarter 2026 Financial Summary ● Total revenues of approximately $1.3 million (including approximately $1,224,000 of product revenues) increased 169% over the 2025 first quarter and 20% over last year’s fourth quarter ● Aurix branded product revenues were","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774926017116/0001437749-26-017116-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Revenue","value":"approximately $1.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}